Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Chiarle

Showing results (61-70 of 156) with videos related to

Pageof 16
Sort By:
Cancer Research|May 8, 2007
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migrationClaudia Voena, Chiara Conte, Chiara Ambrogio, et al.
Cancer Immunology Research|January 8, 2025
Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral BloodSerena Stadler, Rafael B Blasco, Vijay Kumar Singh, et al.
American Journal of Cancer Research|September 19, 2014
STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer modelsFrancesca Marino, Valeria Orecchia, Gabriella Regis, et al.
Blood|September 29, 2005
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomasRoberto Piva, Roberto Chiarle, Andrea D Manazza, et al.
Nature|November 25, 2011
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomasShanshan Duan, Lukas Cermak, Julia K Pagan, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinomaSimon Baldacci, Valérie Grégoire, Enrico Patrucco, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|January 18, 2015
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatmentDiego Alberti, Nicoletta Protti, Antonio Toppino, et al.
Clinical Immunology (Orlando, Fla.)|August 21, 2017
Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1Craig D Platt, Ari J Fried, Rodrigo Hoyos-Bachiloglu, et al.
The American Journal of Pathology|April 12, 2002
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phaseRoberto Chiarle, Yan Fan, Roberto Piva, et al.
Immunology Letters|August 17, 2010
Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytesDaniela Boselli, Josiane Ragimbeau, Luca Orlando, et al.
Pageof 16

Showing results (61-70 of 156) with videos related to

Sort By:
Pageof 16
Cancer Research|May 8, 2007
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migrationClaudia Voena, Chiara Conte, Chiara Ambrogio, et al.
Cancer Immunology Research|January 8, 2025
Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral BloodSerena Stadler, Rafael B Blasco, Vijay Kumar Singh, et al.
American Journal of Cancer Research|September 19, 2014
STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer modelsFrancesca Marino, Valeria Orecchia, Gabriella Regis, et al.
Blood|September 29, 2005
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomasRoberto Piva, Roberto Chiarle, Andrea D Manazza, et al.
Nature|November 25, 2011
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomasShanshan Duan, Lukas Cermak, Julia K Pagan, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinomaSimon Baldacci, Valérie Grégoire, Enrico Patrucco, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|January 18, 2015
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatmentDiego Alberti, Nicoletta Protti, Antonio Toppino, et al.
Clinical Immunology (Orlando, Fla.)|August 21, 2017
Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1Craig D Platt, Ari J Fried, Rodrigo Hoyos-Bachiloglu, et al.
The American Journal of Pathology|April 12, 2002
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phaseRoberto Chiarle, Yan Fan, Roberto Piva, et al.
Immunology Letters|August 17, 2010
Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytesDaniela Boselli, Josiane Ragimbeau, Luca Orlando, et al.
Pageof 16